Bartosz Hudzik: Extended Anticoagulation in Cancer-Associated VTE – Who Is at Higher Bleeding Risk?
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn about a recent article by Isabelle Mahé et al, published in The Lancet Haematology:
”Extended anticoagulation in cancer-associated VTE: who is at higher bleeding risk?
Extended anticoagulation with reduced-dose apixaban has been shown to be non-inferior to full-dose therapy for preventing recurrent VTE in patients with active cancer—while offering fewer clinically relevant bleeding events.
A new post-hoc analysis of the API-CAT trial takes a closer look at predictors of clinically relevant bleeding during extended therapy.
Key findings (12-month follow-up, n=1,766):
Four factors were independently associated with increased bleeding risk:
• Anaemia and/or thrombocytopenia
• Age ≥75 years
• Pulmonary embolism as the index event
• Male sex
Notably:
• Results were consistent across cancer types
• No interaction with apixaban dose was observed
Why this matters
Although API-CAT was not designed to guide anticoagulation discontinuation, these insights may help clinicians better individualize extended anticoagulation, balancing thrombotic protection against bleeding risk in patients with cancer-associated VTE.”
Title: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti for the API-CAT Study Group and API-CAT Investigators
Read the Full Article on The Lancet Haematology
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 22, 2026, 17:21Arrigo Francesco Giuseppe Cicero: Diagnostic and Prognostic Perspectives of Glycocalyx Disruption in Pregnancy
-
Mar 22, 2026, 17:19Veronica Sanchez: Stress from Pregnancy Complications Impacts The Long-Term Cardiovascular Health
-
Mar 22, 2026, 16:21Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
-
Mar 22, 2026, 16:14Andre W. Bourgoyne: Anemia Management as a Comprehensive Hospital Performance Strategy
-
Mar 22, 2026, 16:03Fibrinogen-Guided Management of Postpartum Hemorrhage – Transfusion Medicine KMC Manipal
-
Mar 22, 2026, 15:48Simon Senanu: Diagnostic Significance of Target Cells in Peripheral Blood Smear
-
Mar 22, 2026, 15:43Hayley Evans: What If The Decision Support System Is Part of The Problem?
-
Mar 22, 2026, 15:29Archit Pandharipande: The Burden and Impact of Heavy Menstrual Bleeding in Adolescents with Bleeding Disorders
-
Mar 22, 2026, 15:17Mamtha Balla: Mastering the Lab and Clinical Connection in Hemostasis and Thrombosis